

Technology Pipeline

BIOLOGIC

 **Innovations**
UNIVERSITY OF COLORADO
ANSCHUTZ MEDICAL CAMPUS







Where we are located

CU ANSCHUTZ MEDICAL CAMPUS

The University of Colorado Anschutz Medical Campus is a world-class medical destination at the forefront of transformative science, medicine, education and patient care. The campus encompasses the University of Colorado health professional schools, more than 60 centers and institutes, and two nationally ranked independent hospitals - UCHealth University of Colorado Hospital and Children's Hospital Colorado - that treat more than two million adult and pediatric patients each year. Innovative, interconnected and highly collaborative, the University of Colorado Anschutz Medical Campus delivers life-changing treatments, patient care and professional training and conducts world-renowned research fueled by over \$704 million in research grants.

For more information, visit www.cuanschutz.edu.

 Peptide
  Antibody Based
  Large Molecule
  Nucleotide

 AVAILABLE
 LIMITED AVAILABILITY
 PARTNERED



Dermatology

Xiao-Jing Wang

3302H

PTD-SMAD7 THERAPEUTIC

Endocrine/Metabolism

John C Hutton
(Deceased)

1673H

PEPTIDE AUTOANTIGEN - T1D

Jan Kraus

3197H

TREATMENT OF HOMOCYSTINURIA

Aaron Michels

3588H

INSULIN B MIMOTOPE - T1D



Genitourinary

Sarkis Christopher
Derderian

5155H

MICRORNA - 15B ANTAGOMIR FOR IUGR



T. Rajendra
Kumar

6159H

RECOMBINANT FSH - ART

PRINCIPAL INVESTIGATOR (PI)




 Peptide  Antibody Based  Large Molecule  Nucleotide

 AVAILABLE  LIMITED AVAILABILITY  PARTNERED



Immunology

V. Michael Holers	2545H	C3 ANTIBODIES	
V. Michael Holers	3638H	MAP44 ANTIBODY	
David H Wagner	2376H	CD154 PEPTIDE	

Infectious Disease

Robert Hodges (Deceased)	1323H	ALPHA-HELICAL ANTIMICROBIAL PEPTIDES	
Alexander Horswill	24-211	PEPTIDE INHIBITOR OF STAPH AUREUS	






About our resources

COMPUTATIONAL CHEMISTRY & BIOLOGY CORE

The University of Colorado Anschutz Medical Campus Computational Chemistry and Biology Core Facility provides a wide array of advanced tools and services for computational-based simulations and modeling of chemical and biological systems. Located in the new Skaggs School of Pharmacy and Pharmaceutical Sciences building, the CCB Core offers specialized expertise to researchers in both academia and the biotech/pharmaceutical industry to develop and test hypotheses in silico before executing costly experimental methodologies, reduce the time and costs involved in cutting-edge research, target validation, and novel therapeutic development among other services.

For more information, visit www.pharmacy.cuanschutz.edu/research/core-facilities/computational-chemistry-and-biology-core-facility





 Peptide  Antibody Based  Large Molecule  Nucleotide

 AVAILABLE  LIMITED AVAILABILITY  PARTNERED



Neurology

K. Ulrich ("Ulli") Bayer	2736H	NEUROPROTECTIVE PEPTIDE	
K. Ulrich ("Ulli") Bayer	1933H	CAMKII PEPTIDE	
Paco S Herson	4027H	NEUROPROTECTIVE PEPTIDE	
Paco S Herson	5209H	PEPTIDE INHIBITORS OF TRPM2	
Huntington Potter	4121H	GM-CSF PEPTIDE MIMETIC - NEURODEGENERATION & COGNITION	

Ophthalmology

Uday B Kompella	2886H	TUMSTATIN BASED THERAPY	
Uday B Kompella	3086H	RECOMBINANT LEDGF	
Ram Nagaraj	5122H	PEPTIDES - GALUCOMA	

PRINCIPAL INVESTIGATOR (PI)




About our resources

CENTER FOR DRUG DISCOVERY

The University of Colorado Anschutz Medical Campus Center for Drug Discovery supports drug discovery and development of small molecules, peptides, proteins and antibody-based therapeutics through services like assay development, high-throughput and high-content screening, medicinal chemistry for each stage of development, and pharmacology, including PK, PD, and toxicology. Directed by Dr. Dan LaBarbera, the Center for Drug Discovery also offers additional unique models for microtissues and organoids through 2D and 3D printing as well as phenotypic cell painting.



**Translational
Phase:
From Discovery
to Bedside**



For more information, visit www.pharmacy.cuanschutz.edu/drug-discovery.

To see facility in the news, go to www.youtube.com/watch.



 Peptide  Antibody Based  Large Molecule  Nucleotide

 AVAILABLE  LIMITED AVAILABILITY  PARTNERED

Basic Research

Biologic Discovery

Biologic Development

Clinical Trials

Basic
Research

Identify
Target

Assay
Dev.

Synthesis &
Purification

Animal
Models

Characterization

ADME

Toxicity

Pilot
Scale

Clinical
Trials

Oncology/Hematology

Benjamin Bitler

5591H

CHROMOBOX 2 INHIBITOR PEPTIDE – OVARIAN CANCER



Charles Dinarello

4293H

CHIMERIC IL-37/IGG



Traci Lyons

5954H

ANTI-SEMA7A MAB - BREAST CANCER



Paul Norman

6038H

ANTI-KIR3DL3 MAB -
CHECKPOINT INHIBITORS



Clayton Smith

6191H

AML THERAPY

John Stewart
(Deceased)

1445H

ANTI-BRADYKININ PEPTIDES

Rajeev Vibhakar

0082H

CD99 ANTIBODY - DIPG AND EWING SARCOMA



Zhirui Wang

4936H

CCR4-IL2 BISPECIFIC IMMUNOTOXIN - CUTANEOUS T-CELL LYMPHOMA



Zhirui Wang

6201H

CD47 IMMUNOTOXIN - BREAST CANCER



Zhirui Wang

6218H

CCR4 IMMUNOTOXIN - TNBC



Rui Zhao

24-156

PEPTIDE INHIBITOR OF EYA3



PRINCIPAL INVESTIGATOR (PI)



 Peptide
  Antibody Based
  Large Molecule
  Nucleotide

 AVAILABLE
  LIMITED AVAILABILITY
  PARTNERED



Regenerative Medicine

Kenneth Liechty — 3681H — MICRORNA FOR WOUND HEALING

Rheumatology

John C Cambier — 2233H — ANTI-CD79 MAB - RA AND LUPUS




Kristine Kuhn — 5449H — RUMINOCOCCUS SUBDULOGANULUM: BIOMARKER & THERAPEUTIC TARGET FOR RA



David H Wagner — 5945H — CD40 PEPTIDE INHIBITOR - CANINE AUTOIMMUNE DISEASE

PRINCIPAL INVESTIGATOR (PI)



About us

CU INNOVATIONS

We bring together industry partners, entrepreneurs, and investors to help CU Researchers create biomedical technology that improves the quality of life worldwide. With expertise in patents, copyrights, and licensing, CU Innovations translates discovery into impact through transparent, flexible, best practice intellectual property management services.

Located on the University of Colorado Anschutz Medical Campus, CU Innovations provides access to an extensive portfolio of biomedical technologies, clinical validation opportunities, and resources for startup development.

Let's start a conversation.



CONTACT

David Wang
Assistant Director of BD & Licensing, CU Innovations
University of Colorado Anschutz Medical Campus
david.d.wang@cuanschutz.edu




Innovations

UNIVERSITY OF COLORADO
ANSCHUTZ MEDICAL CAMPUS

Anschutz Health Sciences Building
1890 N. Revere Ct., Suite 6202
Aurora, CO 80045

(303) 724 - 3720
cuinnovations@cuanschutz.edu

 /company/cu-innovations

 @CUInnovations



WEBSITE Scan to view our website and to learn more about how we can best support you >
cuanschutz.edu/cu-innovations

